Human influenza hemagglutinin (HA) is a type of glycoprotein responsible for initiation of virus infections in the human body. Therefore, inhibition of hemagglutinin is important to prevent contagious respiratory illness caused by the influenza virus. Anti-HA antibody is used to prevent the virus from binding with host cells in the body and infecting. Anti-HA antibody plays a key role in neutralizing virus that can cause epidemic and pandemic influenza. Anti-HA antibody facilitates functions like immunoprecipitation, western blot, and indirect immunofluorescence to fight the influenza virus. According to the CDC, it is estimated that the influenza virus has resulted in approximately 35 million cases of illness between 2018 to 2019 in the U.S.
Covid-19 pandemic has reduced and delayed physician visits and hospitalization rate and is expected to reduce the demand of anti-HA antibody for short-term. However, this is expected to balance in long term scenario and growth trends will remains positive for the next decade. Manufacturing and supply chain activities of anti-HA antibody market are expected to hamper due to nation-wide lockdown situation across the majority of countries in the world amid Covid-19 pandemic.
The rise in prevalence of influenza infections is expected to drive anti-HA antibody market growth. With an increase in research and development activities for the anti-HA antibody, the leading industry players are investing in the anti-HA antibody market. For instance, in March 2020 Duke Human Vaccine Institute was awarded US$400 million federal grants for consecutive seven years by National Institute of Allergy and Infectious Diseases (NAID) for development of universal flu vaccine. Increasing awareness and treatment seeking rate of influenza infection are expected to boost anti-HA antibody market growth. Stringent regulatory requirements for approval of drugs can hinder anti-HA antibody market growth.
The global anti-HA antibody market is classified based on the type of antibody, application, sales channel and region.
Based on the type of antibody, anti-HA antibody market is segmented into the following:
Based on the application, the anti-HA antibody market is segmented into the following:
Based on the sales channel, the anti-HA antibody market is segmented into the following:
Increasing prevalence and availability of advanced technology to prevent influenza viral infections will lead towards the growth of the anti-HA antibody market during the forecast period. Monoclonal antibodies (IgM) hold major revenue share in anti-HA antibody market. Therapeutic application is the most common application type of anti-HA antibody market. Hospital pharmacies is the largest distribution channel followed by retail pharmacies in the anti-HA antibody drug market. Online pharmacies segment is expected to observe significant growth rate during the forecast period with increased adoption rate in anti-HA antibody market.
North America will continue to dominate the anti-HA antibody market in the coming decade with a high rate of approvals and commercialization of anti-HA anti therapeutics. The high rate of prevalence of influenza infections increases the demand for anti-HA antibody market in North America. Europe is the second leading region in anti-HA antibody market with increased investments towards research and development activities. Increasing awareness and the treatment-seeking rate will lead to the growth of the anti-HA antibody market in Europe. Asia-pacific is lucrative with a higher growth rate in the anti-HA antibody market during the forecast period with a large patient population in the region. The rise in the number of domestic players with increased product penetration in the Asia-Pacific region will propel the growth of anti-HA antibody market. The Middle East and Africa are expected to observe the least growth in anti-HA antibody market due to less healthcare expenditure in the region. Poor economic conditions in the Middle East and Africa make these market untapped regions with fewer growth opportunities in anti-HA antibody market.
Some key players contributing in anti-HA antibody market are F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., Bristol Myers Squibb Company, Amgen Inc., AbbVie Pharmaceuticals, Eli Lilly and Company, Alexion Pharmaceuticals Inc., GlaxoSmithKline plc., Seattle Genetics, Sanofi S.A., Biogen Inc., AstraZeneca PLC and others.
The report on anti-HA antibody market covers exhaustive analysis on:
Regional analysis for anti-HA antibody market includes
Report on anti-HA antibody market highlights: